Tolerability of PSMA radioligand therapy in metastatic prostate cancer patients with baseline mild to moderate leukopenia

Tolerability of PSMA radioligand therapy in metastatic prostate cancer patients with baseline mild to moderate leukopenia

Abstract Background Aim of this study was to analyze the safety of prostate-specific membrane antigen radioligand therapy (PSMA-RLT) in patients with metastatic castration-resistant prostate cancer (mCRPC) with preexisting mild to moderate leukopenia (CTCAE ≥ 1). Results Thirty-seven mCRPC patients...

Full description

Saved in:
Bibliographic Details
Main Authors: Moritz B. Bastian, Tilman Speicher, Arne Blickle, Caroline Burgard, Julius L. D. Bastian, Mark Bartholomä, Andrea Schaefer-Schuler, Stephan Maus, Samer Ezziddin, Florian Rosar
Format: Article
Language:English
Published: SpringerOpen 2025-07-01
Series:EJNMMI Research
Subjects:
Leukopenia
PSMA
Radioligand therapy
RLT
mCRPC
Safety
Online Access:https://doi.org/10.1186/s13550-025-01280-0
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s13550-025-01280-0

Similar Items